Engineer probiotic bifidobacteria for food and biomedical applications - Current status and future prospective
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Bifidobacteria are members of the human gut microbiota and have shown to exert beneficial effects on their host. Certain strains have a long history of safe and effective use as probiotics. Due to the lack of efficient genetic tools, however, little is known about the molecular mechanisms on which these health-promoting properties are based, thus limiting the synthetic biology applications in bifidobacteria. Here, we discuss the recent development of genetic tools and their engagement in engineering bifidobacteria for food and biomedical applications, from eliminating antibiotic resistance mobile elements and improving robustness to preventing pathogen infections and delivering therapeutics for cancer treatment. In addition, we highlight the application of emerging genome engineering techniques for manipulating the bifidobacterial genome. Finally, we provide our perspective on the future development of synthetic biology techniques and programmed probiotic bifidobacteria with enhanced robustness and designer functionalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Bifidobacteria Expressing Tumstatin Protein for Antitumor Therapy in Tumor-Bearing Mice
Wei, C., Xun, A. Y., Wei, X. X., Yao, J., Wang, J. Y., Shi, R. Y., Yang, G. H., Li, Y. X., Xu, Z. L., Lai, M. G., et al. (2016) · Technology in Cancer Research & Treatment · doi:10.1177/1533034615581977 · Cited by 75
RetractedCommensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Bifidobacteria can protect from enteropathogenic infection through production of acetate
Fukuda, S., Toh, H., Hase, K., Oshima, K., Nakanishi, Y., Yoshimura, K., Tobe, T., Clarke, J. M., Topping, D. L., Suzuki, T., et al. (2011) · Nature · doi:10.1038/nature09646 · Cited by 2,387
Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes
Zhao, L., Zhang, F., Ding, X., Wu, G., Lam, Y. Y., Wang, X., Fu, H., Xue, X., Lu, C., Ma, J., et al. (2018) · Science · doi:10.1126/science.aao5774 · Cited by 2,304
Probiotic bacteria: Selective enumeration and survival in dairy foods
Shah, N. P. (2000) · Journal of Dairy Science · doi:10.3168/jds.s0022-0302(00)74953-8 · Cited by 1,010
Stress Physiology of Lactic Acid Bacteria.
Papadimitriou, K., Alegría, Á., Bron, P. A., de Angelis, M., Gobbetti, M., Kleerebezem, M., Lemos, J. A., Linares, D. M., Ross, P., Stanton, C., et al. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00076-15 · Cited by 914
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Pinto-Sanchez, M. I., Hall, G. B., Ghajar, K., Nardelli, A., Bolino, C., Lau, J. T., Martin, F.-P., Cominetti, O., Welsh, C., Rieder, A., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.05.003 · Cited by 821
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Gurbatri, C. R., Lia, I., Vincent, R., Coker, C., Castro, S., Treuting, P. M., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0876 · Cited by 647
Cited by
Antibiotic perturbations to the gut microbiome
Fishbein, S. R. S., Mahmud, B., & Dantas, G. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00933-y · Cited by 440
“Recent expansions of the toolsets aimed at genetic modification of bacterial and yeast probiotics 197–199 have enabled the engineering of probiotic organisms with more potent and/or targeted anti-pathogenic activities.”
BackgroundZhu, M., Frank, M. W., Radka, C. D., Jeanfavre, S., Xu, J., Tse, M. W., Pacheco, J. A., Kim, J. S., Pierce, K., Deik, A., et al. (2024) · Cell · doi:10.1016/j.cell.2024.07.029 · Cited by 61
An optimized electrotransformation protocol for Lactobacillus jensenii
Fristot, E., Bessede, T., Camacho Rufino, M., Mayonove, P., Chang, H.-J., Zuniga, A., Michon, A.-L., Godreuil, S., Bonnet, J., & Cambray, G. (2023) · PLOS ONE · doi:10.1371/journal.pone.0280935 · Cited by 9
“Broadly speaking, lactobacilli and other lactic acid bacteria hold great promises for various biotechnological and therapeutic applications (Fig 1A) [5, 6].”
Background
Metadata
- Authors
- Zuo, F., Chen, S., & Marcotte, H.
- Venue
- Biotechnology Advances
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 45
- Pages
- 107654
- ISSN
- 0734-9750 (ISSN-L)
- OpenAlex
- W3095995628
- Cited by
- 73
- References
- 22
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Engineer probiotic bifidobacteria for food and biomedical applications - Current status and future prospective. https://app.cochat.ai/papers/10.1016/j.biotechadv.2020.107654
- The paper
- Zuo, F., Chen, S., & Marcotte, H. (2020). Engineer probiotic bifidobacteria for food and biomedical applications - Current status and future prospective. Biotechnology Advances. https://doi.org/10.1016/j.biotechadv.2020.107654
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.